HIF1A: Difference between revisions
New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1H2K' size='340' side='right' caption='Caption for this structure' scene=''> This is a default text for you... |
Michal Harel (talk | contribs) No edit summary |
||
| (19 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='1H2K' size='340' side='right' caption='Human hypoxia-inducible factor 1 alpha C-terminal activation domain residues 776-829 (mustard) complex with factor inhibiting HIF1 ( grey, green) complex with sulphate, oxalylglycine and Fe+2 (grey) (PDB code [[1h2k]])' scene=''> | |||
<StructureSection load='1H2K' size='340' side='right' caption=' | |||
== Introduction == | |||
'''HIF1α''' is a subunit of the transcription factor HIF1, together with HIF1β <ref name="Neill>O’Neill, Luke A. J., Rigel J. Kishton, and Jeff Rathmell. 2016. “A Guide to Immunometabolism for Immunologists.” Nature Reviews Immunology 16 (9): 553–65. https://doi.org/10.1038/nri.2016.70. | |||
</ref>. HIF1α is part exclusively of HIF1 whilst HIF1β is part of other transcription factors as well as HIF1. | |||
HIF1 is related to glucose metabolism, stimulation of circulation and it was first described in hypoxia conditions, but it is now known that it can be activated also in normoxia situations, acting especially in the polarization of immune cells to more inflammatory phenotypes <ref name="Neill"</ref>. | |||
The N-terminal region of HIF1α contains a basic helix-loop-helix (bHLH) structure, that is responsible for the interaction with the hypoxia responsive elements (HRE) [5’-(G/C/T)-ACGTGC- (G/T)-3’] present in many enhancers regions of different genes, and a PERARNT-SIM (PAS) domain that are responsible for dimerization with HIF1β. HIF1β is also known as aryl hydrocarbon receptor nuclear translocator (ARNT) <ref name= "Loboda">Loboda, Agnieszka, Alicja Jozkowicz, and Jozef Dulak. 2010. “HIF-1 and HIF-2 Transcription Factors — Similar but Not Identical.” Molecules and Cells 29 (5): 435–42. https://doi.org/10.1007/s10059-010-0067-2.</ref>. | |||
HIF1α also contains a transactivation domain (TAD) that interacts with CREB binding protein (CBP) and p300, transcription co-activators. In sufficient O2 concentration <ref name="Yang">YANG, Chao, Zhang-Feng ZHONG, Sheng-Peng WANG, Chi-Teng VONG, Bin YU, and Yi-Tao WANG. 2021. “HIF-1: Structure, Biology and Natural Modulators.” Chinese Journal of Natural Medicines 19 (7): 521–27. https://doi.org/10.1016/s1875-5364(21)60051-1. | |||
</ref>, TAD can suffer hydroxylation by prolyl-hydroxylase (PHD) proteins, which inhibits the interaction between those co-activating factors and marks the subunit to ubiquitination by von Hippel-Lindau tumor suppressor protein (VHL), part of the E3 ubiquitin-protein ligase, and consequently degradation in the proteasome. Other interactions with different groups can inhibit the activity of HIF1α as well <ref name="Watts"/>. | |||
== Function == | == Function == | ||
HIF1α is one of the subunits of HIF1. HIF1 is a transcription factor that binds to HREs in the genome sequence and regulates genes involved in angiogenesis, vascular regulation, erythropoiesis, iron metabolism, cellular growth, apoptosis, extracellular matrix metabolism and glycolysis <ref name="Watts"/>. Although it was first described in hypoxia situations, it is now known to be active in normoxia situations as well | |||
<ref name="Neill">O’Neill, Luke A. J., Rigel J. Kishton, and Jeff Rathmell. 2016. “A Guide to Immunometabolism for Immunologists.” Nature Reviews Immunology 16 (9): 553–65. https://doi.org/10.1038/nri.2016.70. | |||
</ref> . | |||
In hypoxia, the PHDs mark HIF1α to ubiquitination and consequently degradation in the proteasome complex. This process occurs when molecular oxygen (O2) is present <ref name="Watts"/>. | |||
In immune cells, HIF1 can be activated in normoxia and its effect in the regulation of glycolysis is directly linked to their polarization, contributing to an inflammatory profile <ref name="Neil"/>. | |||
== Disease == | == Disease == | ||
== | Hypoxia-inducible factors (HIFs) are essential in the progression of various diseases, including cancer and conditions such as peripheral arterial disease, pulmonary arterial hypertension, and sleep apnea. They also play a significant role in regulating insulin signaling and obesity. <ref name="Feng"> Feng, Zhihui, Xuan Zou, Yaomin Chen, Hanzhi Wang, Yingli Duan, and Richard K Bruick. 2018. “Modulation of HIF-2α PAS-B Domain Contributes to Physiological Responses.” Proceedings of the National Academy of Sciences of the United States of America 115 (52): 13240–45. https://doi.org/10.1073/pnas.1810897115.</ref> | ||
Under hypoxic conditions, HIFs are stabilized and activate the expression of genes related to cellular adaptation to oxygen deprivation. In the presence of oxygen, HIFs are degraded, but during hypoxia, they form active complexes and promote important cellular changes.<ref name="Cowman"> Cowman, Sophie J., and Mei Yee Koh. 2022. “Revisiting the HIF Switch in the Tumor and Its Immune Microenvironment.” Trends in Cancer 8 (1): 28–42. https://doi.org/10.1016/j.trecan.2021.10.004.</ref> | |||
Hypoxia is a common feature in solid tumors and their metastases, leading to the activation of HIFs, which influence gene expression in both tumor cells and immune cells in the tumor microenvironment. This affects tumor progression and treatment response. <ref name="Cowman"/> | |||
In particular, HIF-1α is crucial in the initiation of certain types of cancer, such as clear cell renal cell carcinoma (ccRCC), and is elevated in pre-neoplastic stages. <ref name="Cowman"/> | |||
== Structural highlights == | == Structural highlights == | ||
| Line 15: | Line 32: | ||
</StructureSection> | </StructureSection> | ||
== References == | |||
<references/> | ==References== | ||
<references /> | |||